MPN

P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET.

A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Adding pelabresib to a JAK inhibitor may improve multiple aspects of myelofibrosis, including spleen size, symptoms and bone marrow fibrosis.

Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with navtemadlin.

CURE celebrated seven MPN Heroes, who ranged from patients to medical professionals, on the contributions they made in the community.

Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, research showed.

Second-line treatment with Inrebic has been shown to be beneficial for patients with myelofibrosis previously treated with Jakafi.

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.

Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting.

Keri is also a true partner in the management and care of the whole patient.

The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy.

Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.

Researchers identified five traits that may increase a person’s chance of experiencing polycythemia vera progression.

The development of new or worsening anemia did not decrease Jakafi’s efficacy in treating primary or secondary myelofibrosis.

I have an incurable cancer, which forces me — and my loved ones — to be ever-adapting in this physical and emotional battle.

Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.

Childbirth rates have been reduced by 22% in women with MPNs, compared with women without MPNs, researchers found.

Treatment with rusfertide led to a decrease in the need for blood draws and decreased levels of red blood cells in patients with polycythemia vera.

Patients with myeloproliferative neoplasms should keep their care team up to date on any symptoms they’re experiencing, an expert said.

Patients with MPNs who are JAK2V617F- and CALR-positive had different bacterial compositions compared with people without MPNs, research found.

Thomas Silver discusses how a community of support helped a patient when his bone marrow transplant was delayed.

A doctor reflected on what it was like treating patients with myeloproliferative neoplasms years ago and how much treatments have improved.

An expert explained the benefits of patients with myeloproliferative neoplasms finding a community of people with similar diagnoses.

New treatments and ongoing trials are providing more options and better outcomes for patients with myeloproliferative neoplasms, an expert explained.

Dr. Douglas Tremblay of the Ichan School of Medicine explains the necessity of cytoreductive therapy for patients with MPNs such as essential thrombocythemia and polycythemia vera.

After being diagnosed with essential thrombocythemia, Marilyn Kay Edwards was not told much about her disease.

When caring for his wife with myelofibrosis, Ed Bartholemy focused on making her life as fun and positive as possible, despite her limitations.